Zevra Therapeutics (ZVRA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ZVRA Zevra Therapeutics

Watchlist

8.150
-0.280-3.32%

Close Oct 31 16:00 ET

8.150
0.0000.00%

Post 20:01 ET

428.83MMarket Cap-4766P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
ReutersOct 31 07:30 ET
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
GlobeNewswireOct 31 07:30 ET
Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline
Zacks Oct 29 09:05 ET
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
Moomoo NewsOct 14 06:34 ET · Ratings
Buy Rating Affirmed for Zevra Therapeutics Based on Strong NPV and Future Market Potential
TipRanksOct 14 05:46 ET · Ratings
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
GlobeNewswireOct 10 07:30 ET

Comments

Meltyy

Sep 25 06:31

See FDA PDUFA update 👀 👇

🚨 This Week’s PDUFAs:
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...

Jaguar8

Sep 24 06:55

NEWS

$Zevra Therapeutics (ZVRA.US)$
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
Zevra Therapeutics (NASDAQ: ZVRA) announced that top-line data from its Phase 2 clinical trial of KP1077 for idiopathic hypersomnia (IH) will be presented at Sleep Europe 2024. The trial (NCT05668754) was a placebo-controlled, double-blind, randomized withdrawal study evaluating the safety and tolerability of KP1077 (serdexmethylp...